Dec 19, 2008
Vermont Jury Awards $800,000 for Failure to Monitor Coumadin in Medical Malpractice Wrongful Death Lawsuit
A Franklin County jury returned on October 30, 2008, a $800,000 verdict in a medical malpractice lawsuit to the family of a woman who died while on the blood thinner Coumadin for a history of deep vein thrombosis and a heart condition. Patients on Coumadin require close monitoring of their blood's ability to clot by a test called an INR. Her doctor failed to properly monitor her INR values and as a result, Mrs. Stone's blood became too thin, depleted of clotting factors, and susceptible to uncontrolled bleeding. After grazing her ear, she became unresponsive and was taken to the hospital where her INR was found to be 12.29, a dangerously high level. (The target therapeutic range was 2 to 3.) A CT scan revealed that she had suffered a massive intracranial hemorrhage which caused herniation of her brain. Attorney for the plaintiff was Chris Maley, Burlington, Vermont.
Nov 23, 2008
An article in the Burlington Free Press, on seniors and falls includes some interesting Vermont facts on falls...
- "One in five hip fracture patients over age 65 die within a year after surgery, and one in four have to spend a year or more recuperating in a nursing home.
- Falls are the leading cause of catastrophic injury in older adults.
- Among older adults, falls are the leading cause of injury deaths.
- More than 95 percent of hip fractures among those over 65 are caused by falling.
- Vermont has one of the highest rates of death from falls nationwide."
Oct 27, 2008
According to the report...
"According to the state's complaint, Pfizer's painkiller Bextra had FDA approval for use in treating arthritis and menstrual pain, but Pfizer marketed it for use treating acute pain, pain associated with surgery and for reducing use of narcotic painkillers. The state referred to these as "off-label" uses.Pfizer did not admit to any wrongdoing in the settlement. For more information, click on this link: Vermont's share of Pfizer Settlement.
The FDA pulled Bextra from the market in 2005 due to concerns it increased the risk of heart attacks and strokes. Published reports from the last week show Pfizer also paying $745 million to settle personal injury claims and $89 million for consumer fraud class-action lawsuits, all dealing with Bextra or Celebrex."
Oct 21, 2008
Oct 7, 2008
Vermont is one of 32 states involved in the settlement.
Aug 19, 2008
"A captive insurance company is established, for example, when a corporation develops a subsidiary, which is licensed in Vermont, and uses it to provide various types of insurance to the corporate parent.... Medical malpractice is one of the most quickly growing fields for the industry..."Bermuda and the Cayman Islands are the only two locales that are more active than Vermont in the captive insurance market.
Aug 15, 2008
"Diana Levine, a professional guitarist who lost an arm to gangrene after a receiving a shot to treat a migraine headache in 2000.See the full article here: Plaintiffs' Lawyers Fight Restrictions On Product-Liability Suits
Ms. Levine won $6.8 million in her lawsuit against Wyeth, which makes the antinausea drug, phenergan, that was given to her. A Vermont jury and that state's Supreme Court found that Wyeth hadn't sufficiently warned the public and doctors about the drug's dangers if improperly injected.
Wyeth has argued that the company is protected because the Food and Drug Administration had approved its label. The government is supporting Wyeth's position, on behalf of the FDA."
Aug 10, 2008
Wyeth claims its product was sufficiently labeled, which included warnings about the potential risk of gangrene if the drug was improperly injected. The company has since appealed the case to the Supreme Court, creating a potential landmark ruling that would make it easier for drugmakers to protect themselves from product liability lawsuits. That’s because the majority of lawsuits against drugmakers involve the same issue, whether or not the company had proper warnings on its label. The Food and Drug Administration (FDA) approve these labels.See article for more information.